225 related articles for article (PubMed ID: 15086644)
1. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.
Kivitz AJ; Greenwald MW; Cohen SB; Polis AB; Najarian DK; Dixon ME; Moidel RA; Green JA; Baraf HS; Petruschke RA; Matsumoto AK; Geba GP;
J Am Geriatr Soc; 2004 May; 52(5):666-74. PubMed ID: 15086644
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
Weaver AL; Messner RP; Storms WW; Polis AB; Najarian DK; Petruschke RA; Geba GP; Tershakovec AM
J Clin Rheumatol; 2006 Feb; 12(1):17-25. PubMed ID: 16484875
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
[TBL] [Abstract][Full Text] [Related]
4. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.
Truitt KE; Sperling RS; Ettinger WH; Greenwald M; DeTora L; Zeng Q; Bolognese J; Ehrich E;
Aging (Milano); 2001 Apr; 13(2):112-21. PubMed ID: 11405384
[TBL] [Abstract][Full Text] [Related]
6. Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
Battisti WP; Katz NP; Weaver AL; Matsumoto AK; Kivitz AJ; Polis AB; Geba GP
J Pain; 2004 Nov; 5(9):511-20. PubMed ID: 15556830
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
[TBL] [Abstract][Full Text] [Related]
9. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
[TBL] [Abstract][Full Text] [Related]
10. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
Katz N; Ju WD; Krupa DA; Sperling RS; Bozalis Rodgers D; Gertz BJ; Gimbel J; Coleman S; Fisher C; Nabizadeh S; Borenstein D;
Spine (Phila Pa 1976); 2003 May; 28(9):851-8; discussion 859. PubMed ID: 12941996
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
Day R; Morrison B; Luza A; Castaneda O; Strusberg A; Nahir M; Helgetveit KB; Kress B; Daniels B; Bolognese J; Krupa D; Seidenberg B; Ehrich E
Arch Intern Med; 2000 Jun; 160(12):1781-7. PubMed ID: 10871971
[TBL] [Abstract][Full Text] [Related]
13. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
Smugar SS; Schnitzer TJ; Weaver AL; Rubin BR; Polis AB; Tershakovec AM
Curr Med Res Opin; 2006 Jul; 22(7):1353-67. PubMed ID: 16834834
[TBL] [Abstract][Full Text] [Related]
14. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
Cannon GW; Caldwell JR; Holt P; McLean B; Seidenberg B; Bolognese J; Ehrich E; Mukhopadhyay S; Daniels B
Arthritis Rheum; 2000 May; 43(5):978-87. PubMed ID: 10817549
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Reicin AS; Shapiro D; Sperling RS; Barr E; Yu Q
Am J Cardiol; 2002 Jan; 89(2):204-9. PubMed ID: 11792343
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee.
Zhao SZ; Dedhiya SD; Bocanegra TS; Fort JG; Kuss ME; Rush SM
Clin Ther; 1999 Jan; 21(1):205-17. PubMed ID: 10090436
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee.
Weaver A; Rubin B; Caldwell J; McMahon FG; Lee D; Makarowski W; Offenberg H; Sack M; Sikes D; Trapp R
Clin Ther; 1995; 17(4):735-45. PubMed ID: 8565037
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee.
Schnitzer TJ; Kivitz AJ; Lipetz RS; Sanders N; Hee A
Arthritis Rheum; 2005 Dec; 53(6):827-37. PubMed ID: 16342089
[TBL] [Abstract][Full Text] [Related]
20. A double-masked comparison of Naprelan and nabumetone in osteoarthritis of the knee. Naprelan Study Group.
Fleischmann RM; Flint K; Constantine G; Kolecki B
Clin Ther; 1997; 19(4):642-55. PubMed ID: 9377610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
